MARKET

DMK

DMK

DMK Pharmaceuticals Corporation
NASDAQ
0.6890
+0.0324
+4.93%
After Hours: 0.6548 -0.0342 -4.96% 19:59 09/29 EDT
OPEN
0.5910
PREV CLOSE
0.6566
HIGH
0.7299
LOW
0.5910
VOLUME
1.29M
TURNOVER
0
52 WEEK HIGH
21.70
52 WEEK LOW
0.4505
MARKET CAP
6.45M
P/E (TTM)
-0.0624
1D
5D
1M
3M
1Y
5Y
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 4d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Investorplace · 4d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
DMK Pharmaceuticals Corporation Granted Patent Number 3061323 Titled 'An Opioid For Use To Reduce And/Or Treat Drug Addiction'
Benzinga · 5d ago
Weekly Report: what happened at DMK last week (0918-0922)?
Weekly Report · 6d ago
Weekly Report: what happened at DMK last week (0911-0915)?
Weekly Report · 09/18 10:01
More
About DMK
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.

Webull offers kinds of DMK Pharmaceuticals Corp stock information, including NASDAQ:DMK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DMK stock methods without spending real money on the virtual paper trading platform.